Radiosensitizers
What are radiosensitizers?
Radiosensitizers are agents that increase the sensitivity of tumor cells to ionizing radiation. They improve the effectiveness of radiotherapy, which is often limited by intrinsic or acquired cellular radioresistance. There are different classes of radiosensitizers, including high-quality radiosensitizer peptides provided by JPT Peptide Technologies.
How do radiosensitizers enhance radiosensitivity?
Depending on their mode of action, radiosensitizers enhance the overall effectiveness of radiotherapy by either increasing radiation-induced DNA damage or impairing cellular recovery mechanisms. To achieve these effects, a range of radiosensitivity strategies has been developed that target specific biological pathways. These include DNA damage repair, stress-response signaling, pro-survival pathways, cell cycle regulation, and tumor hypoxia.
Among these strategies, inhibition of the NF-kb pathway is widely used, as its activation promotes transcriptional programs involved in cell survival, inflammation, and apoptosis regulation. In many cancer cells, this pathway is abnormally active and contributes to therapy resistance following irradiation. NF-kb inhibitors suppress anti-apoptotic signaling and limits DNA repair, making tumor cells more susceptible to radiation-induced cytotoxicity.
Radiosensitizer peptides by JPT Peptide Technologies
At JPT Peptide Technologies, we offer two reliable radiosensitizer peptides, SN50 and SN52. They inhibit the NF-kB pathway by blocking nuclear translocation of the NF-kB complex and preventing its transcriptional activity. Based on the nuclear localization sequence (NLS) of the NF-kB subunits p50 and p52, these peptides are also fused with a cell-penetrating sequence derived from K-FGF to enable cellular uptake. Applying our trustworthy NF-kB inhibitors support robust experimental designs for researchers working in the fields of radiotherapy and cancer research.
List of our radiosensitizer peptides
Can’t find what you’re looking for? You can also choose your own peptide sequence, amount, and purity. Our Custom Peptide Synthesis team will guide you through the entire process.
Explore JPT Peptide Technologies peptide catalog if you’re interested in purchasing additional peptides!
Research areas and applications
Our high-quality radiosensitizer peptides are primarily used by scientists as research tools in cancer biology and radiotherapy. However, due to their selective inhibition of canonical and non-canonical NF-kB signaling, they are also being investigated in a broader range of preclinical research settings. The list below reflects published experimental studies and highlight potential applications of these peptides across additional research areas.
| Research Area | SN50 | SN52 |
| Oncology & Radiotherapy | Widely investigated in preclinical tumor models as broad-spectrum radiosensitizers to study canonical NF-kB-mediated therapy resistance and tumor cell survival. | Investigated as selective radiosensitizers in prostate cancer and other non-canonical NF-kB-driven tumor models, particularly in aggressive and radioresistant cancers. |
| Inflammatory Conditions | Extensively studied in experimental models of acute inflammation, including acute lung injury (ALI), sepsis, and ventilator-induced lung injury (VILI), with a focus on cytokine regulation. | Explored in chronic and tumor-associated inflammatory models to study the non-canonical signaling. |
| Immunology & Vaccines | Investigated for modulating immune responses, including experimental studies on vaccine response modulation and preclinical immunotherapy research. | Used in immuno-oncology research to examine p52-RelB-mediated immune evasion within the tumor microenvironment. |
| Neurobiology & Cell Stress | Studied in experimental models of traumatic brain injury (TBI) to investigate neuroinflammation and cellular stress responses. | Employed as a low-toxicity comparator in neural cell assays to assess selective inhibition of the non-canonical pathway. |
| Pharmacology & Toxicity | Used as a reference tool for studying broad NF-kB inhibition, including assessment of pathway suppression and associated cytotoxic effects. | Serves as a research prototype for selective NF-kB inhibition, demonstrating reduced effects on normal cells in comparative studies. |
| Metabolism & Cardiovascular Research | Experimentally applied to investigate NF-kB-associated mechanisms in obesity-related inflammation and hypertension models. | |
| Translational Imaging & Nuclear Medicine | Explored in preclinical nuclear medicine research as part of the development of targeted radiopharmaceutical strategies. |
Challenges and future directions
- Pharmacokinetics and delivery: Because these NF-kB inhibitors are peptide-based, they may show limited stability and availability in vivo. Improving formulation and delivery approaches, such as nanoparticle-based or targeted systems, could enhance their stability and overall effectiveness.
- Selectivity and off-target effects: Although the peptides selectively inhibit NF-kB signaling pathways, their effects on normal tissues need to be carefully evaluated to reduce off-target effects and limit toxicity.
- Combination strategies: Future research should explore combination approaches with immune checkpoint inhibitors, targeted therapies, or DNA damage response inhibitors, to further improve radiosensitivity and treatment response.
- Biomarker-guided use: Further identifying biomarkers linked to NF-kB pathway activation may help select tumors that are more likely to respond to SN50 or SN52-based radiosensitizing strategies.